Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Budesonide in PT027 vs Pulmicort (ELBRUS)
NCT03934333Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2019
- Primary completion
- Sep 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of salbutamol + budesonide in asthma (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from time zero to infinity at Day 2, Area under the plasma concentration-curve from time zero to time of last quantifiable concentration at Day 2 and 1 more. Started May 2019; status: completed.
02
Drugs
salbutamol + budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03934333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03934333.